SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-018422
Filing Date
2024-05-09
Accepted
2024-05-09 16:05:49
Documents
60
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 618851
2 ex31-1.htm EX-31.1 17620
3 ex31-2.htm EX-31.2 17660
4 ex32-1.htm EX-32.1 6911
5 ex32-2.htm EX-32.2 6799
  Complete submission text file 0001493152-24-018422.txt   3462620

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20240331.xsd EX-101.SCH 27843
7 XBRL CALCULATION FILE ltrn-20240331_cal.xml EX-101.CAL 45332
8 XBRL DEFINITION FILE ltrn-20240331_def.xml EX-101.DEF 84288
9 XBRL LABEL FILE ltrn-20240331_lab.xml EX-101.LAB 229336
10 XBRL PRESENTATION FILE ltrn-20240331_pre.xml EX-101.PRE 183580
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 450536
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

IRS No.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 24930455
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)